Wasatch Advisors LP Sells 973,341 Shares of Certara, Inc. $CERT

Wasatch Advisors LP lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 18.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,298,825 shares of the company’s stock after selling 973,341 shares during the quarter. Wasatch Advisors LP’s holdings in Certara were worth $28,157,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CERT. Northwestern Mutual Wealth Management Co. increased its position in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the period. Osaic Holdings Inc. grew its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Certara during the second quarter worth approximately $83,000. Finally, Gamco Investors INC. ET AL bought a new position in shares of Certara during the fourth quarter worth approximately $90,000. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ:CERT opened at $8.01 on Thursday. The firm has a 50 day moving average of $6.70 and a 200-day moving average of $6.50. Certara, Inc. has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.22 billion, a PE ratio of -17.80 and a beta of 1.44.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period last year, the business earned $0.07 earnings per share. The business’s revenue was down 10.8% compared to the same quarter last year. On average, equities research analysts predict that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Craig Hallum dropped their price target on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Tuesday, May 12th. Morgan Stanley reduced their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Stephens dropped their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, BMO Capital Markets cut their target price on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.28.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.